Seres Therapeutics (MCRB) Q1 2026 Earnings
Seres Therapeutics reported Q1 2026 revenue of $358.0K. Diluted EPS came in at $-2.08 (+7.1% YoY), missed the $-1.88 consensus by $0.20.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Seres Therapeutics's Q1 2026 earnings report.
Seres Therapeutics (MCRB) reported Q1 2026 earnings on May 5, 2026 before market open.
Seres Therapeutics reported revenue of $358.0K and diluted EPS of $-2.08 for Q1 2026.
Revenue beat the consensus estimate of $358.0K by -. EPS missed the consensus estimate of $-1.88 by $0.20.
Compared to the same quarter a year prior, diluted EPS grew 7.1% from $-2.24.
You can read the 8-K earnings release (0001193125-26-205009) and the 10-Q periodic report (0001193125-26-205434) directly on SEC EDGAR. The filing index links above go to sec.gov.